Antibiotic stewardship — the responsible use of antimicrobials to slow resistance — and animal welfare are deeply interconnected. The same practices that drive antibiotic overuse (crowded housing, stress, inadequate nutrition) harm animal welfare. Conversely, good welfare conditions reduce disease burden, lowering antibiotic need. In 2025, these fields are increasingly integrated in policy, practice, and advocacy.
The Antibiotic-Welfare Connection
Historically, antibiotics served two distinct functions in livestock production:
Therapeutic use: Treating individual sick animals or groups experiencing disease outbreaks
Subtherapeutic use for growth promotion: Low-dose antibiotic supplementation to accelerate growth — a practice now banned in the EU, UK, USA, and many other jurisdictions
Both uses reflect and affect animal welfare:
High therapeutic use indicates high disease burden, which itself represents poor welfare
Growth-promotion antibiotic use masked welfare problems by allowing animals to survive conditions that would otherwise cause greater mortality
Prophylactic mass medication (treating entire groups preventively) is often a substitute for welfare and biosecurity improvements
Global Scale: Approximately 70% of all medically important antibiotics used globally are consumed in livestock production. The WHO has classified antimicrobial resistance as one of the greatest global health threats. Farm animal welfare improvements that reduce disease incidence directly reduce antibiotic use.
Growth Promoters: History and Welfare Legacy
The use of antibiotics as growth promoters (AGPs) represented one of the most significant intersections of welfare and resistance concerns:
AGPs were used at subtherapeutic levels in poultry, pig, and cattle feeds from the 1950s through 2000s
Their growth-promoting effect partly worked by reducing subclinical infectious disease that would otherwise suppress growth
AGP use therefore enabled higher stocking densities and less sanitary conditions while maintaining commercial growth rates
Banning AGPs has forced welfare improvements (better housing, biosecurity) as essential prerequisites for maintaining productivity
EU Ban Legacy: The EU banned antibiotic growth promoters in 2006. The transition demonstrated both the welfare-stewardship link and its complexity: initial post-ban periods saw increased therapeutic antibiotic use in some countries as producers managed disease outbreaks that AGPs had previously suppressed. Long-term, the ban drove genuine improvements in hygiene and housing.
Welfare Drivers of Disease and Antibiotic Use
Housing and Stress
The welfare conditions that drive antibiotic overuse are well-documented:
Overcrowding: Increases pathogen transmission, reduces immune function through competition stress, and creates conditions for rapid disease spread requiring mass medication
Poor ventilation: Respiratory pathogens (PRRS, enzootic pneumonia in pigs; infectious bronchitis in poultry; BRD in cattle) thrive in poorly ventilated facilities
Stress-mediated immunosuppression: Chronic stress reduces lymphocyte function and inflammatory response, increasing susceptibility to infection
Inadequate nutrition: Deficiencies in vitamins, minerals, and protein impair immune function
Poor hygiene: All-in-all-out systems with proper cleaning dramatically reduce between-batch pathogen carryover
The Vicious Cycle
Poor welfare creates a cycle that entrenches antibiotic dependency:
Overcrowded, stressful conditions → high disease pressure
High disease pressure → high antibiotic use (therapeutic and prophylactic)
Antibiotic use → resistance development in farm pathogens
Increased disease burden reinforces dependence on antibiotics as management tool
Breaking the Cycle: Research consistently shows that investments in welfare improvements — better housing, reduced stocking density, enrichment, outdoor access — reduce disease incidence and antibiotic use simultaneously. Farms transitioning to higher-welfare production systems typically report 30–70% reductions in antibiotic use within 2–3 years.
Specific Welfare-Stewardship Interventions
Intervention
Welfare Benefit
Antibiotic Reduction
Reduce stocking density
Less competition, injury, stress
Significant — less respiratory and enteric disease
All-in-all-out management
Reduces disease carryover
Major — breaks transmission cycles
Improved ventilation
Reduces respiratory stress
Major — respiratory disease is leading antibiotic use driver
Outdoor access/range
Behavioral needs, lower stress
Moderate — lower respiratory disease risk
Enrichment provision
Reduces frustration and injury
Reduces wound infection from aggression
Pain management protocols
Direct welfare benefit
Reduces secondary infections from unmanaged pain
Enhanced biosecurity
Reduces disease morbidity
Major — fewer disease introductions
Vaccination programs
Reduces disease suffering
Significant — replaces antibiotic use for many diseases
Species-Specific Stewardship Challenges
Pigs
The pig industry faces particular antibiotic use challenges:
Post-weaning diarrhea (PWD) has historically been managed with preventive antibiotic use
EU ban on prophylactic antibiotic use (effective 2022) has driven major shifts toward zinc oxide supplementation, vaccines, and improved nutrition
Zinc oxide itself is being phased out due to environmental concerns, creating further pressure for welfare-based solutions
Gestation crate bans in progressive jurisdictions have improved sow welfare and reduced stress-related immune suppression
Poultry
Respiratory disease (Mycoplasma, infectious bronchitis, Newcastle disease) is a major antibiotic use driver
Coccidiosis — a major antibiotic and coccidiostat use driver — is better managed in outdoor systems through dose exposure and immunity development
Water-based antibiotic delivery (mass medication) is being phased out in progressive markets in favor of individual treatment approaches
Dairy and Beef Cattle
Dry cow therapy (blanket antibiotic treatment at drying off) is being replaced by selective dry cow therapy based on somatic cell count assessment
Selective dry cow therapy reduces antibiotic use while maintaining mastitis control
Bovine respiratory disease (BRD) in feedlots is a major use driver — welfare improvements (weaning stress reduction, transport protocols) reduce susceptibility
EU Veterinary Medicines Regulation (2022, fully effective 2022): Prohibits prophylactic group antibiotic use and restricts metaphylaxis (group treatment when some animals show disease). Requires prescription for all antibiotic use. Mandates antibiotic usage data collection. Creates "reserve antibiotic" categories with strict prescription criteria. This is the world's most comprehensive framework integrating stewardship and welfare.
UK: Post-Brexit, the UK maintained EU-level standards and has developed its own voluntary reduction targets through the Responsible Use of Medicines in Agriculture (RUMA) Alliance. The UK has achieved over 50% reduction in antibiotic use in food-producing animals since 2014.
USA: The FDA's Veterinary Feed Directive (VFD, effective 2017) ended over-the-counter antibiotic use for growth promotion. Remaining medically important antibiotic use requires veterinary oversight. Stewardship is largely voluntary, with industry-led programs having mixed adherence.
The Role of Veterinarians
Veterinarians are increasingly positioned as both welfare advocates and stewardship gatekeepers:
Herd health programs that identify disease root causes (welfare and management factors) reduce antibiotic treatment cycles
Prescription-only antibiotic regimes require vet involvement, creating stewardship touchpoints
Proactive welfare consultancy prevents disease crises requiring emergency mass medication
Farm animal vets are increasingly trained in both welfare assessment and stewardship planning as integrated disciplines
Vaccination: Major disease control tool; ongoing development of novel vaccines for previously antibiotic-dependent conditions
Probiotics and prebiotics: Evidence growing for gut health maintenance, particularly in post-weaning pigs and poultry
Phage therapy: Bacteriophages targeting specific pathogens — promising for antibiotic-resistant infections
Organic acids: Feed acidifiers reduce gut pathogen loads in poultry
Essential oils: Some show antimicrobial properties; evidence base developing
Improved diagnostics: Rapid pathogen identification allows targeted treatment rather than broad-spectrum empirical therapy
Consumer and Market Drivers
Consumer concerns about antibiotic resistance are driving market-based stewardship:
Major food service companies (McDonald's, Subway, Chipotle) have committed to sourcing meat raised without medically important antibiotics
"No Antibiotics Ever" (NAE) and "Raised Without Antibiotics" (RWA) labels command price premiums
Supermarket own-brand commitments in UK and EU markets drive significant producer change
These market commitments simultaneously incentivize welfare improvements as disease-prevention strategy
Conclusion
Antibiotic stewardship and animal welfare are not separate policy domains — they are deeply interlinked. The welfare conditions that cause animal suffering also drive antibiotic overuse and resistance development. Conversely, investments in welfare improvements are investments in stewardship: healthier, less stressed animals need fewer antibiotics. The 2025 regulatory landscape is increasingly recognizing this integration, with prescription requirements, prophylaxis bans, and welfare standards being developed as complementary tools. Progress on both fronts simultaneously serves animal welfare, public health, and the long-term sustainability of animal agriculture.